Latest Investments News

MyState Limited has finalized its merger with Auswide Bank, positioning the combined entity for significant cost savings and earnings growth while maintaining strong capital and customer metrics.

MyState Limited has reported a stable underlying net profit of $17.5 million for the half-year, maintaining customer growth and a robust capital position as it prepares to merge with Auswide Bank.

MyState Limited reported a modest revenue increase but an 8.9% decline in statutory profit for the half year ended December 2024, while declaring a fully franked interim dividend. The company is set to complete a transformative merger with Auswide Bank, aiming for earnings accretion from FY26.

Citigroup announces a fully franked AUD 2.25 dividend for CBA CitiFirst Self-Funding Instalment MINIs, effective 20 February 2025, aligning with CBA ordinary shares' dividend dates.

Brisbane Broncos Limited has announced a fully franked ordinary dividend of AUD 0.02 per share for the 2024 financial year, signaling steady returns for shareholders.

Brisbane Broncos Limited reported a solid $5.72 million net profit for 2024, underpinned by revenue growth and a decade-long extension to their NRL Club Licence. Despite missing the NRL finals, commercial strength and NRLW success buoyed the club's financial position.

Ardea Resources Limited has made significant progress on its Kalgoorlie Nickel Project (KNP) Goongarrie Hub, supported by a fully funded $98.5 million Definitive Feasibility Study (DFS) led by a Japanese consortium. The project is positioned as a long-life, low-cost nickel-cobalt operation critical to the global battery supply chain.

FFI Holdings Limited has announced a fully franked ordinary dividend of AUD 0.10 per share for the half-year ending December 2024, payable in April 2025. The company also offers shareholders a Dividend Reinvestment Plan with a 5% discount.

FFI Holdings Limited reported a 7.5% rise in revenue and a 7.6% increase in net profit after tax for the half year ended December 31, 2024, alongside the declaration of a fully franked interim dividend.

Atturra Limited reports a robust first half of FY25 with revenue growth nearing 28%, driven by recent acquisitions and expanding service offerings, while updating full-year guidance amid cautious government sector risks.

Nyrada Inc. posted a significant $2.46 million loss for H1 FY25, driven by increased R&D spend, while advancing its lead drug NYR-BI03 into first-in-human trials following regulatory approval.

Zelira Therapeutics has received a $1.15 million cash refund from the Australian Government’s R&D Tax Incentive Scheme, bolstering its working capital to advance clinical development and business operations.